Singapore-based biotech company, Hummingbird Bioscience, renowned for its pioneering work in cancer antibody development, is now shifting its focus towards the development of precision drugs for immunology and inflammatory diseases like lupus and inflammatory bowel disease. Leveraging its expertise in antibody-drug conjugates originally designed for cancer treatment, the company is gearing up to file regulatory approvals in Asia, Europe, and the US within the next 12 to 18 months to commence clinical trials for these novel drugs. These drugs consist of antibodies with the ability to precisely target specific disease-related molecules coupled with drug payloads intended to treat the ailment effectively.
Recognized for its innovation, Hummingbird Bioscience recently received an accolade from the World Intellectual Property Organisation (WIPO), underscoring its commitment to intellectual property strategy and commercialization success. The company’s robust IP portfolio and licensing-based business model have positioned it as a leader in the biotech industry, facilitating global translation of innovative therapies developed in Singapore. Looking ahead, Hummingbird aims to expand its product pipeline with a strong focus on immunology and inflammatory diseases, acknowledging the substantial unmet clinical need in this area.
Immunology and inflammatory diseases present a significant global health burden, affecting up to 10% of the world’s population and driving a thriving market for therapeutics, which is estimated to reach $257 billion by 2032. Hummingbird’s approach to targeting these diseases involves developing antibody-drug conjugates that specifically address overactive or destructive immune cells, employing drugs to modulate harmful immune responses. By enabling targeted drug delivery to immune cells, these conjugates offer a promising solution to enhance treatment safety and efficacy, overcoming limitations associated with conventional small molecule drugs commonly used for such conditions.
Incorporating artificial intelligence (AI) into its drug discovery and development processes, Hummingbird Bioscience is leveraging cutting-edge technologies to accelerate the identification of key target cells and antigens involved in immunology and inflammatory diseases. By utilizing AI to comprehend complex biological processes underlying these diseases, the company aims to enhance the precision and effectiveness of its antibody-drug conjugates, catering to the intricate nature of these ailments. The company’s commitment to advancing precision medicine through innovative approaches underscores its dedication to addressing critical unmet needs in healthcare.
Key Takeaways:
– Hummingbird Bioscience is transitioning from cancer antibody development to targeting immunology and inflammatory diseases with precision drugs, leveraging antibody-drug conjugates.
– The company’s recognition by WIPO for its robust intellectual property strategy highlights its commitment to innovation and commercialization success.
– With a focus on leveraging artificial intelligence in drug development, Hummingbird aims to accelerate the identification of key targets in immunology and inflammatory diseases, addressing critical unmet clinical needs.
– By developing targeted antibody-drug conjugates for immune cells involved in disease pathogenesis, Hummingbird is poised to revolutionize treatment approaches for complex inflammatory conditions, enhancing safety and efficacy.
Tags: biopharma, antibody-drug conjugates, regulatory, biotech
Read more on straitstimes.com